Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model-Reference-Cited by-同舟云学术

Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model

Published:2020-11 Issue: Volume:492 Page:174-184
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Yamamoto Jun,Miyake Kentaro,Han Qinghong,Tan Yuying,Inubushi Sachiko,Sugisawa Norihiko^ORCID,Higuchi Takashi,Tashiro Yoshihiko^ORCID,Nishino Hiroto,Homma Yuki,Matsuyama Ryusei,Chawla Sant P.,Bouvet Michael,Singh Shree Ram^ORCID,Endo Itaru,Hoffman Robert M.

Funder

Pancreas Research Foundation of Japan

JSPS KAKENHI

Yokohama City University research grant “KAMOME Project”

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference57 articles.

1. Recent trends in survival of patients with pancreatic cancer in Germany and the United States;Sirri;Pancreas,2016

2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Canc. Res.,2014

3. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N. Engl. J. Med.,2011